Ceftazidime As Single-agent Therapy for Gram-negative Aerobic Bacillary Osteomyelitis

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 1987 Oct 1

PMID 3124734

Citations 4

Authors

M C Bach

D M Cocchetto

Affiliations

Soon will be listed here.

Abstract

The cases of 28 patients who received ceftazidime as single-agent therapy in prospective clinical trials for biopsy culture-proven osteomyelitis were reviewed. These cases all involved infection caused by gram-negative aerobic bacilli, the most frequent agent (83% of patients) being Pseudomonas aeruginosa. Posttreatment follow-up for patients with acute osteomyelitis was continued for at least 6 months, while follow-up for at least 12 months was done for patients with chronic osteomyelitis. A regimen of 2 g of ceftazidime intravenously every 12 h was used for most patients. The overall cure rates were 77% (acute disease) and 60% (chronic disease). Development of resistance to ceftazidime was not problematic, and the drug was well tolerated. Ceftazidime is effective for serious gram-negative bacillary osteomyelitis, including that due to P. aeruginosa. The twice-daily regimen did not cause major organ toxicity, eliminating the need for concentration monitoring and making it feasible to use the drug for home parenteral therapy.

Citing Articles

Systemic antibiotic therapy for chronic osteomyelitis in adults.

Spellberg B, Lipsky B Clin Infect Dis. 2011; 54(3):393-407.

PMID: 22157324 PMC: 3491855. DOI: 10.1093/cid/cir842.

Prolonged treatment of chronic Pseudomonas aeruginosa osteomyelitis with a combination of two effective antibiotics.

Lucht R, Fresard A, Berthelot P, Farizon F, Aubert G, DORCHE G Infection. 1994; 22(4):276-80.

PMID: 8002088 DOI: 10.1007/BF01739916.

Oral ciprofloxacin treatment of Pseudomonas aeruginosa osteomyelitis.

Dan M, Siegman-Igra Y, Pitlik S, Raz R Antimicrob Agents Chemother. 1990; 34(5):849-52.

PMID: 2360823 PMC: 171704. DOI: 10.1128/AAC.34.5.849.

Ofloxacin versus parenteral therapy for chronic osteomyelitis.

Gentry L Antimicrob Agents Chemother. 1991; 35(3):538-41.

PMID: 2039205 PMC: 245046. DOI: 10.1128/AAC.35.3.538.

References

Miller E, Semian D . Gram-negative osteomyelitis following puncture wounds of the foot. J Bone Joint Surg Am. 1975; 57(4):535-7. View

Greenberg R, Tice A, Marsh P, Craven P, Reilly P, Bollinger M . Randomized trial of ciprofloxacin compared with other antimicrobial therapy in the treatment of osteomyelitis. Am J Med. 1987; 82(4A):266-9. View

Mackowiak P, Jones S, Smith J . Diagnostic value of sinus-tract cultures in chronic osteomyelitis. JAMA. 1978; 239(26):2772-5. DOI: 10.1001/jama.239.26.2772. View

Verbist L, Verhaegen J . GR-20263: a new aminothiazolyl cephalosporin with high activity against Pseudomonas and Enterobacteriaceae. Antimicrob Agents Chemother. 1980; 17(5):807-12. PMC: 283880. DOI: 10.1128/AAC.17.5.807. View

OCALLAGHAN C, Acred P, Harper P, Ryan D, Kirby S, Harding S . GR 20263, a new broad-spectrum cephalosporin with anti-pseudomonal activity. Antimicrob Agents Chemother. 1980; 17(5):876-83. PMC: 283891. DOI: 10.1128/AAC.17.5.876. View

Tanphaichitra D, Bussayanond A, CHRISTENSEN O . The combination of pivmecillinam and pivampicillin in the treatment of acute enteric fever. J Antimicrob Chemother. 1981; 8(1):23-8. DOI: 10.1093/jac/8.1.23. View

Rotimi V, Turk D . Transferable multiple antibiotic resistance in Haemophilus influenzae. J Antimicrob Chemother. 1981; 8(3):187-92. DOI: 10.1093/jac/8.3.187. View

Armstrong G, Wise R, Brown R, Hancox J . Comparison of ceftazidime and cefamandole pharmacokinetics and blister fluid concentrations. Antimicrob Agents Chemother. 1981; 20(3):356-8. PMC: 181700. DOI: 10.1128/AAC.20.3.356. View

Pichichero M, Friesen H . Polymicrobial osteomyelitis: report of three cases and review of the literature. Rev Infect Dis. 1982; 4(1):86-96. DOI: 10.1093/clinids/4.1.86. View

10.

Norrby S, Burman L, Linderholm H, Trollfors B . Ceftazidime: pharmacokinetics in patients and effects on the renal function. J Antimicrob Chemother. 1982; 10(3):199-206. DOI: 10.1093/jac/10.3.199. View

11.

Mackowiak P, Smith J . Polymicrobial infections in osteomyelitis. Rev Infect Dis. 1983; 5(1):167-8. DOI: 10.1093/clinids/5.1.167. View

12.

Sommers D, Walters L, van Wyk M, Harding S, Paton A, Ayrton J . Pharmacokinetics of ceftazidime in male and female volunteers. Antimicrob Agents Chemother. 1983; 23(6):892-6. PMC: 184996. DOI: 10.1128/AAC.23.6.892. View

13.

Walstad R, Hellum K, Blika S, Dale L, Fredriksen T, Myhre K . Pharmacokinetics and tissue penetration of ceftazidime: studies on lymph, aqueous humour, skin blister, cerebrospinal and pleural fluid. J Antimicrob Chemother. 1983; 12 Suppl A:275-82. DOI: 10.1093/jac/12.suppl_a.275. View

14.

Scully B, Neu H . Clinical efficacy of ceftazidime. Treatment of serious infection due to multiresistant Pseudomonas and other gram-negative bacteria. Arch Intern Med. 1984; 144(1):57-62. DOI: 10.1001/archinte.144.1.57. View

15.

MacGregor R, Gentry L . Imipenem/cilastatin in the treatment of osteomyelitis. Am J Med. 1985; 78(6A):100-3. DOI: 10.1016/0002-9343(85)90109-3. View

16.

Gentry L . Treatment of skin, skin structure, bone, and joint infections with ceftazidime. Am J Med. 1985; 79(2A):67-74. DOI: 10.1016/0002-9343(85)90264-5. View

17.

Gentry L, Macko V, Lind R, Heilman A . Ticarcillin plus clavulanic acid (Timentin) therapy for osteomyelitis. Am J Med. 1985; 79(5B):116-21. DOI: 10.1016/0002-9343(85)90142-1. View

18.

Sheftel T, Mader J . Randomized evaluation of ceftazidime or ticarcillin and tobramycin for the treatment of osteomyelitis caused by gram-negative bacilli. Antimicrob Agents Chemother. 1986; 29(1):112-5. PMC: 180374. DOI: 10.1128/AAC.29.1.112. View

19.

De Bastiani G, Nogarin L, Molinaroli F, Bragantini A, Fostini R . Use of ceftazidime in the treatment of osteomyelitis and osteoarthritis. Int J Clin Pharmacol Ther Toxicol. 1986; 24(12):677-9. View

20.

Gilbert D, Tice A, Marsh P, Craven P, Preheim L . Oral ciprofloxacin therapy for chronic contiguous osteomyelitis caused by aerobic gram-negative bacilli. Am J Med. 1987; 82(4A):254-8. View